Forest Laboratories Submits NDA for Cariprazine
November 28, 2012 at 06:24 AM EST
Forest Laboratories, (NYSE: FRX ) and Gedeon Richter Plc. announced that Forest has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for cariprazine, a potent dopamine D3/D2
